ZA201701772B - Pharmaceutical formulation for reducing bladder spasms and method of use thereof - Google Patents
Pharmaceutical formulation for reducing bladder spasms and method of use thereofInfo
- Publication number
- ZA201701772B ZA201701772B ZA2017/01772A ZA201701772A ZA201701772B ZA 201701772 B ZA201701772 B ZA 201701772B ZA 2017/01772 A ZA2017/01772 A ZA 2017/01772A ZA 201701772 A ZA201701772 A ZA 201701772A ZA 201701772 B ZA201701772 B ZA 201701772B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical formulation
- bladder spasms
- reducing bladder
- reducing
- spasms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2014/057200 WO2016048301A1 (en) | 2014-09-24 | 2014-09-24 | Pharmaceutical formulation for reducing bladder spasms and method of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201701772B true ZA201701772B (en) | 2018-08-29 |
Family
ID=55581626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/01772A ZA201701772B (en) | 2014-09-24 | 2017-03-10 | Pharmaceutical formulation for reducing bladder spasms and method of use thereof |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3197441A4 (ko) |
| JP (1) | JP2017532301A (ko) |
| KR (1) | KR20170049613A (ko) |
| CN (1) | CN107072971A (ko) |
| AU (1) | AU2014407186A1 (ko) |
| BR (1) | BR112017006141A2 (ko) |
| CA (1) | CA2962004A1 (ko) |
| IL (1) | IL250827A0 (ko) |
| MX (1) | MX2017003878A (ko) |
| RU (1) | RU2017113827A (ko) |
| SG (1) | SG11201702069XA (ko) |
| WO (1) | WO2016048301A1 (ko) |
| ZA (1) | ZA201701772B (ko) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7025129B2 (ja) * | 2017-05-17 | 2022-02-24 | 小林製薬株式会社 | 筋痙攣治療剤 |
| WO2019240755A1 (en) * | 2018-06-11 | 2019-12-19 | Wellesley Pharmaceuticals, Llc | Pharmaceutical compositions and methods for weight loss |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0328060D0 (en) * | 2003-12-04 | 2004-01-07 | Sod Conseils Rech Applic | Botulinum toxin treatment |
| MX2007014496A (es) * | 2005-05-20 | 2008-02-11 | Omeros Corp | Composiciones de inhibidor de ciclooxigenasa y antagonista de los canales de calcio y metodos para usarlas en procedimientos urologicos. |
| CN101460150B (zh) * | 2006-03-31 | 2014-02-12 | 鲁比康研究私人有限公司 | 用于口腔崩解片剂的可直接压片复合物 |
| US20090264530A1 (en) * | 2008-04-16 | 2009-10-22 | Nickell Robert P | Combined nsaid and acetaminophen formulation and method |
| US20120010294A1 (en) * | 2010-07-08 | 2012-01-12 | Dill David A | Compositions and methods for the inhibition of muscle contraction |
| AU2012211960B2 (en) * | 2011-02-04 | 2016-12-01 | Taris Biomedical Llc | Implantable device for controlled release of low solubility drug |
| MY173582A (en) * | 2012-01-04 | 2020-02-04 | Wellesley Pharmaceuticals Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| CN103191430A (zh) * | 2012-01-04 | 2013-07-10 | 韦尔斯利医药有限公司 | 用于缓解尿频的缓释制剂及其使用方法 |
-
2014
- 2014-09-24 JP JP2017512011A patent/JP2017532301A/ja active Pending
- 2014-09-24 AU AU2014407186A patent/AU2014407186A1/en not_active Abandoned
- 2014-09-24 CN CN201480082173.0A patent/CN107072971A/zh active Pending
- 2014-09-24 WO PCT/US2014/057200 patent/WO2016048301A1/en not_active Ceased
- 2014-09-24 MX MX2017003878A patent/MX2017003878A/es unknown
- 2014-09-24 EP EP14902616.3A patent/EP3197441A4/en not_active Withdrawn
- 2014-09-24 KR KR1020177011054A patent/KR20170049613A/ko not_active Withdrawn
- 2014-09-24 BR BR112017006141-4A patent/BR112017006141A2/en not_active Application Discontinuation
- 2014-09-24 SG SG11201702069XA patent/SG11201702069XA/en unknown
- 2014-09-24 CA CA2962004A patent/CA2962004A1/en not_active Abandoned
- 2014-09-24 RU RU2017113827A patent/RU2017113827A/ru not_active Application Discontinuation
-
2017
- 2017-02-27 IL IL250827A patent/IL250827A0/en unknown
- 2017-03-10 ZA ZA2017/01772A patent/ZA201701772B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107072971A (zh) | 2017-08-18 |
| CA2962004A1 (en) | 2016-03-31 |
| RU2017113827A (ru) | 2018-10-24 |
| JP2017532301A (ja) | 2017-11-02 |
| AU2014407186A1 (en) | 2017-03-09 |
| IL250827A0 (en) | 2017-04-30 |
| WO2016048301A1 (en) | 2016-03-31 |
| KR20170049613A (ko) | 2017-05-10 |
| BR112017006141A2 (en) | 2018-02-06 |
| MX2017003878A (es) | 2017-06-28 |
| EP3197441A1 (en) | 2017-08-02 |
| EP3197441A4 (en) | 2018-05-23 |
| RU2017113827A3 (ko) | 2018-10-24 |
| SG11201702069XA (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250496A0 (en) | A device that includes an expandable body and a method of use | |
| IL252172B (en) | Expandable drug delivery devices and methods of use | |
| SG11201609966SA (en) | Drug delivery system and method of use | |
| PT3104814T (pt) | Aparelho para administração supra-coroidal de agente terapêutico | |
| IL251246A0 (en) | Therapeutically active compounds and methods of use | |
| IL252199A0 (en) | Spray drying device and method of use | |
| IL248060A0 (en) | System and method for therapeutic management of cough | |
| GB201514760D0 (en) | Compounds and method of use | |
| GB201421197D0 (en) | Apparatus and method of use thereof | |
| EP3194377A4 (en) | Heterocycle substituted amino-pyridine compounds and methods of use thereof | |
| IL249348A0 (en) | A new preparation and method for synthesis | |
| EP3152281A4 (en) | Defoaming agent and associated methods of use | |
| SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
| GB2548269B (en) | Exercise system and method of use thereof | |
| SG11201610383YA (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
| ZA201701772B (en) | Pharmaceutical formulation for reducing bladder spasms and method of use thereof | |
| IL248035A0 (en) | Database and the method of using it | |
| GB201408171D0 (en) | Formulation and method of manufacture | |
| EP3197779A4 (en) | Danger avoidance apparatus and method of use | |
| GB201517613D0 (en) | Scaffolding apparatus and method of use thereof | |
| EP3143000A4 (en) | Dosage of dasotraline and method for treatment of adhd | |
| AU2014905266A0 (en) | Formulation and method of use | |
| GB201416797D0 (en) | Contianer and method of use thereof | |
| GB201403200D0 (en) | Cushion means and method of use thereof | |
| GB201408738D0 (en) | Components and methods for formulation of components |